Founder-CEO Interview Series

/

Sharon Cunningham

Ms. Sharon Cunningham is a seasoned pharmaceutical executive and co-founder of Shorla Oncology, a leading specialty pharmaceutical company focused on developing innovative oncology treatments for women, children, and patients with rare cancers. As CEO and board member, she oversees Shorla’s mission to address unmet medical needs and improve patient outcomes.

With a strong background in finance and a proven track record in the pharmaceutical industry, Cunningham has played a pivotal role in Shorla’s growth and success. The company’s recent launch of two oncology drugs in the U.S. marks a significant milestone in its commitment to delivering life-changing therapies.

Founder-CEO Interview Series

with Sharon Cunningham

You are a chartered accountant turned biotech Founder-CEO. Can you share your journey with us? 

After graduating with a Bachelor of Science in Finance, I trained to become a Chartered Accountant with PwC. I later secured a role as a Management Accountant with pharmaceutical company, EirGen Pharma, progressed to Financial Controller and then Head of Finance. During my time there, I obtained my executive MBA. In 2018 I co-founded Shorla Oncology, a specialty pharmaceutical company developing and commercializing innovative oncology drugs addressing unmet needs. I come from an entrepreneurial family and I always knew I would run my own business eventually but I wanted to spend time in practice and industry and gain as much formal education as possible in order to maximise my knowledge and skills, build an industry network and ultimately enhance my credibility to ensure success. 

Shorla Oncology focuses on re-innovating existing oncology treatments. Could you elaborate on the unique challenges and advantages of this approach compared to developing entirely new drugs?

Prior to founding the company, my co-founder and I identified shortcomings and limitations with existing pharmaceuticals where we found that oncology treatments were limited, often in shortage and inadequate for the target populations. 

New approaches to Research and Development in the pharmaceutical industry are increasingly needed as intense pressure is applied to reduce the cost of prescription drugs and expedite medicines to treat unmet medical needs including rare orphan diseases. Identification of novel applications for existing active substances compliments traditional drug discovery by mitigating high monetary and time-related costs and risks.

New drug development while potentially transformative, carries significant risk and cost. Taking established and proven oncology treatments and doing something novel or different with them to address key areas of unmet need is an approach that we take at Shorla to create differentiated, superior products, creating Intellectual Property, while utilising a defined regulatory pathway to register such speciality drug products with the U.S. Food and Drug Authority (FDA). 

What drives you? 

Prior to founding Shorla, I found myself inspired and fascinated by other entrepreneurial journeys, particularly having joined EirGen Pharma at an early stage and experiencing that company grow and succeed. I was highly motivated to do something meaningful and purposeful with my life; to have a wider impact and create positive change for patients and I’ve always had an appetite for risk. In truth, the fear of failure to achieve our goals and as a result, letting stakeholders down is what drives me every single day in addition to feeling compelled to make my loved ones proud and especially to inspire my three young sons.  

With several products in the pipeline, what are some of the key milestones Shorla Oncology is aiming to achieve in the next 12-18 months, and what impact do you foresee these having on the market?

We have four product launches imminent and executing commercially on these opportunities in the near term will be fundamental to our success. Our product development strategy has evolved throughout the evolution of our business (originally solely focussing on developing products in-house to later acquiring or in-licencing products to de-risk and expand the pipeline) and this approach has become our strategy for longer-term growth and revenue optimization by complimenting our in-house product development pipeline and maximizing the commercial infrastructure we have built in the U.S. with synergistic acquisition or in-licensing opportunities. 

Can you highlight some career achievements you take pride in? 

Our vision of improving lives through science and innovation has been realised many times with a robust pipeline in development and a portfolio on the market. I felt a massive sense of accomplishment when the first patient was treated with our first drug; this proved to me that we could take an idea, bring it through the regulatory process and successfully launch it commercially and that fills me with pride and optimism for the future of our business.  

Who or what has shaped who you are? 

My mother and my grandmother who lived with us growing up have been a huge influence on me and my mother continues to inspire me every day. She has illustrated the true meaning of equality as a strong, independent businesswoman and taught me that anything is possible if you put your mind to it. More recently, my three young sons have become my ‘why’ and given me a reason to strive for success; I’m determined to inspire them and demonstrate the meaning of equality to them.

Congratulations on the numerous awards and recognitions, such as being an EY Entrepreneur of the Year finalist and making Ireland’s Best Young Entrepreneur list. Can you share the key qualities, strategies, or efforts that you believe have contributed to these accolades?

The awards and recognitions can be credited to our fantastic team who go above and beyond every day. We strive to live our company values in the pursuit of our mission together and I’m continuously inspired by our innovative and tenacious professionals and their steadfast commitment to achieving our goals collaboratively and compassionately to keep the momentum going.

I was very fortunate to have spent a large part of my career working in a pharmaceutical company at a senior level. I watched the company grow from a start-up with a handful of people to a multinational company employing over 200 people in the South East of Ireland. I worked on various transactions, including a large fundraise and the due diligence associated with the sale of the company to a large US company. The training I got taught me how important the fundamentals are in order for a company to function optimally. Creating agile business systems, covering legal and taxation bases and paying extremely close attention to the numbers is essential. A mindset of embracing change and not fearing it is at the core of our product development strategy and our ability to innovate. 

What is one interesting fact about yourself that few people know of (a hobby, etc.)?

I’m an adrenalin seeker and love trying new activities whether in the sky, on the snow or in the ocean!

What is your view on failure? 

Running a venture capital-backed entrepreneurial company with several stakeholders comes with significant pressure to execute and succeed.

Our journey so far has been a very rewarding experience but not without significant challenges no different to any start-up company. I now know that failures along the journey are inevitable and it’s how you react that will determine the outcome. While overall I fear failure and do my utmost to prevent it, I now understand that sometimes there are circumstances outside of my control and as a result I’m more accepting and better able to manage the defeats. I feel very fortunate to have my amazing co-founder Orlaith Ryan; we can support each other through the bad days and celebrate the good days together. 

Given your diverse experience and success, what advice would you offer to young entrepreneurs looking to make a significant impact in the healthcare and pharmaceutical sectors?

Three things:

1) Mentoring – Identify an informal and confidential mentor you trust and admire early in your career and don’t be afraid to ask for help when you need it- you’ll be surprised at how willing successful people are to help you.

2) Branding – Be very conscious of branding – both the company or product brand and your own personal brand. People form relationships with and do business with people and not companies. Identify what makes you unique and stand out from the crowd and embrace it – every single day.

3) Network – Concentrate your efforts on working smarter and not necessarily harder. Never underestimate the power of your network; take time to grow it and engage with it consistently- your connections will open endless doors for you and strong relationships are key to future opportunities. 

Insights

Related articles

Margrit Schwarz

Who inspired you to get into the life sciences? My interest for life science was nurtured by my father, who was both a chemist and a photographer; he took me along on hikes and then to the lab where I spent hours staring through a microscope, examining the things I had just picked up on the trail. It instilled in me a deep fascination for all things ‘Nature’, from patterns of life that repeat regardless of scale, to endless curiosity for – simply put – why things are the way they are!

Read More

Stephan Christgau

You have an extensive background in both academia and the biotech industry, with over 60 peer-reviewed papers and multiple patents. How has your experience as a researcher shaped your approach as a life sciences investor and entrepreneur?

I think it gives a different perspective as an investor, when you have actually had operational experience. Having started companies and worked with f.ex. patent strategy, development plans and CRO selection and monitoring is not only something I hear about in the board room, but something I have actually done myself.

That said, one should of course also be humble and recognize that one’s own experience is only directly relevant in few cases, and of course we engage experts and other stakeholders in all cases, but it is nevertheless a different perspective one gets from having started and run companies.

The scientific background, and ability to grasp and challenge scientific backgrounds of projects and companies, is essential for an investor in the life science space, and indeed I believe most of my peers in other venture funds have scientific and/or clinical backgrounds.

Read More

John Boghossian

Can you share the inspiration and vision behind founding Kadence Bio?
The inspiration for Kadence Bio stemmed from our founders’ early investigations into potential acute treatments for mood disorders, where they explored different classes of alkaloid small molecules. We discovered a compound scaffold with a distinctive pharmacokinetic profile that also exhibited an unexpected effect of delayed ejaculation. This – rather unexpected! – The finding was corroborated by the elucidation of its potential mechanism of action. 
We then identified a significant unmet need, as no FDA-approved treatments exist for premature ejaculation, a condition that affects at least 1 in 20 men and their partners globally and hinders intimacy and well-being in these relationships. We quickly decided to found Kadence Bio, with a vision of cultivating sexual and mental well-being by developing novel treatments for sexual health and mood disorder applications.

Read More

Matthieu de Kalbermatten

Tell us about your background.
For the last 15 years, I have held management positions in medtech and biotech companies, mainly in the field of cardiology. Having trained as an ETH engineer, I’ve always been attracted by cutting-edge technology at the service of innovation, which led me to decide 8 years ago to take over the management of the biotech start-up CellProthera, a specialist in stem cells, which offers immense potential for therapeutic innovation.

Read More